HQY vs WST
HealthEquity vs West Pharmaceutical Services — AI-powered side-by-side comparison
VS
WST
West Pharmaceutical Services
67
Buy
| Metric | HQY | WST |
|---|
| AI Score |
64
|
67
|
| Price |
$106.83
|
$352.13
|
| P/E Ratio |
38.75×
|
44.99×
|
| ROE |
10.2%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.7%
|
36.8%
|
| Debt / Equity |
0.48×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.2%
|
| RSI (14) |
65.8
|
61.3
|
| Beta |
0.21
|
1.138
|
| Expected Upside |
+1.0%
|
—
|
AI Committee View
Current Innellis committee reasoning for HQY versus WST.
WST leads by 3 points.
WST scores 67/100 (Buy) versus HQY at 64/100 (Buy).
HQY Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 15.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.3% signals elevated volatility — Risk
WST Committee View
83% agreement
6 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is p/e of 44.1 is expensive by classic value standards. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 18.5% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 44.1 is expensive by classic value standards — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical